Suppr超能文献

CKD-EPI 和 EKFC GFR 估算方程:在成人中实施方程的选择、性能和其他考虑因素。

CKD-EPI and EKFC GFR Estimating Equations: Performance and Other Considerations for Selecting Equations for Implementation in Adults.

机构信息

Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.

Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.

出版信息

J Am Soc Nephrol. 2023 Dec 1;34(12):1953-1964. doi: 10.1681/ASN.0000000000000227. Epub 2023 Oct 5.

Abstract

SIGNIFICANCE STATEMENT

New eGFR equations from Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and European Kidney Function Consortium (EKFC) using creatinine (eGFRcr), cystatin C (eGFRcys), and both (eGFRcr-cys) have sufficient accuracy for use in clinical practice, leading to uncertainty in selecting equations for implementation. The authors evaluated performance of equations in an independent population of 4050 adults and evaluated other considerations important for implementation. They found that CKD-EPI and EKFC equations are approaching convergence, with better performance of eGFRcr-cys equations in the overall group and fewer differences among race, sex, and age subgroups than eGFRcr equations. Larger differences among eGFRcr equations reflect regional population differences in creatinine, forcing a trade-off between accuracy and uniformity in global implementation of eGFRcr equations. More widespread use of cystatin C could avoid this trade-off.

BACKGROUND

New CKD-EPI and EKFC eGFR equations using eGFRcr, eGFRcys, and both (eGFRcr-cys) have sufficient accuracy for use in clinical practice. A better understanding of the equations, including their performance in race, sex and age subgroups, is important for selection of eGFR equations for global implementation.

METHODS

We evaluated performance (bias and P 30 ) of equations and methods used for equation development in an independent study population comprising 4050 adults pooled from 12 studies. The mean (SD) measured GFR was 76.4 (29.6) ml/min per 1.73 m 2 and age 57.0 (17.4) years, with 1557 (38%) women and 579 (14%) Black participants.

RESULTS

Coefficients for creatinine, cystatin C, age, and sex in the CKD-EPI and EKFC equations are similar. Performance of the eGFRcr-cys equations in the overall population (bias <±5 ml/min per 1.73 m 2 and P 30 >90%) was better than the eGFRcr or eGFRcys equations, with fewer differences among race, sex, and age subgroups. Differences in performance across subgroups reflected differences in diversity of source populations and use of variables for race and sex for equation development. Larger differences among eGFRcr equations reflected regional population differences in non-GFR determinants of creatinine.

CONCLUSION

CKD-EPI and EKFC equations are approaching convergence. It is not possible to maximize both accuracy and uniformity in selecting one of the currently available eGFRcr equations for implementation across regions. Decisions should consider methods for equation development in addition to performance. Wider use of cystatin C with creatinine could maximize both accuracy and uniformity of GFR estimation using currently available equations.

摘要

意义陈述

来自慢性肾脏病流行病学合作组织(CKD-EPI)和欧洲肾脏功能联盟(EKFC)的新 eGFR 方程使用肌氨酸酐(eGFRcr)、胱抑素 C(eGFRcys)和两者(eGFRcr-cys),在临床实践中具有足够的准确性,导致在选择实施方程时存在不确定性。作者在一个由 4050 名成年人组成的独立人群中评估了方程的性能,并评估了实施其他重要考虑因素。他们发现 CKD-EPI 和 EKFC 方程正在趋同,eGFRcr-cys 方程在整个组中的性能更好,并且在种族、性别和年龄亚组之间的差异比 eGFRcr 方程更小。eGFRcr 方程之间的更大差异反映了肌氨酸酐在不同地区人群中的差异,这在全球实施 eGFRcr 方程的准确性和一致性之间造成了权衡。更广泛地使用胱抑素 C 可以避免这种权衡。

背景

新的 CKD-EPI 和 EKFC eGFR 方程使用 eGFRcr、eGFRcys 和两者(eGFRcr-cys),在临床实践中具有足够的准确性。更好地了解这些方程,包括它们在种族、性别和年龄亚组中的性能,对于选择用于全球实施的 eGFR 方程非常重要。

方法

我们在一个由 12 项研究中合并的 4050 名成年人组成的独立研究人群中评估了方程的性能(偏倚和 P 30)和用于方程开发的方法。测量的 GFR 平均值(标准差)为 76.4(29.6)ml/min/1.73m2,年龄为 57.0(17.4)岁,其中 1557 名(38%)女性和 579 名(14%)黑人参与者。

结果

CKD-EPI 和 EKFC 方程中肌氨酸酐、胱抑素 C、年龄和性别的系数相似。eGFRcr-cys 方程在总体人群中的性能(偏倚<±5 ml/min/1.73m2 和 P 30>90%)优于 eGFRcr 或 eGFRcys 方程,在种族、性别和年龄亚组之间的差异较小。亚组之间性能的差异反映了源人群多样性以及种族和性别方程开发中变量使用的差异。eGFRcr 方程之间的更大差异反映了肌氨酸酐非 GFR 决定因素在不同地区人群中的差异。

结论

CKD-EPI 和 EKFC 方程正在趋同。在选择一个目前可用的 eGFRcr 方程在不同地区实施时,不可能同时最大化准确性和一致性。决策应考虑方程开发方法以及性能。更广泛地使用肌氨酸酐和胱抑素 C 可以利用目前可用的方程最大化 GFR 估计的准确性和一致性。

相似文献

引用本文的文献

10
Chronic Kidney Disease Progression-A Challenge.慢性肾脏病进展——一项挑战
Biomedicines. 2024 Sep 27;12(10):2203. doi: 10.3390/biomedicines12102203.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验